Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

Abstract

Erlotinib failed to show an improvement in PFS or OS compared with docetaxel in an EGFR-unselected patient population.